Codeine, CYP2D6, and Clinical Blind Spots

Why the “Mild Opioid” May Not Be So Mild

Codeine is widely used around the world, often available over the counter, and frequently perceived as a “safe” opioid. But this reputation obscures the complexity of how it works—and why it doesn’t work for everyone. While codeine has some weak intrinsic activity at the µ-opioid receptor, its clinically meaningful pain relief depends largely on its conversion into morphine via the CYP2D6 enzyme. This makes CYP2D6 function a critical factor in how effective—or dangerous—codeine can be, and a key reason why it’s a good candidate for use in pharmacogenetic testing protocols used by medical professionals.

Why CYP2D6 Status Matters More Than Most Think

Once absorbed, codeine is metabolized via CYP2D6 into morphine, which is responsible for both its analgesic and euphoric effects. But patients differ drastically in how active their CYP2D6 pathway is:

• Poor metabolisers may convert too little codeine to morphine, rendering the drug ineffective.

• Ultrarapid metabolisers convert too much, too quickly — raising the risk of toxicity and fatal respiratory depression, especially in children or postoperative patients.

Pharmacogenomic testing guidelines explicitly contraindicate codeine in both extremes. Yet many UK clinicians still prescribe codeine without a CYP2D6 pharmacogenomic test, despite growing access to DNA pharmacogenetic testing services. 

The Drug–Drug Interaction Layer

Beyond genetics, CYP2D6 is highly sensitive to drug-drug interactions. Certain medications can inhibit this enzyme, reducing codeine’s efficacy even in those with a normal genotype. This phenomenon is called phenoconversion.

Well-known CYP2D6 inhibitors include:

• SSRIs like fluoxetine and paroxetine

• Bupropion

• Some beta-blockers and antipsychotics

Even patients with normal CYP2D6 genes can experience reduced analgesia and subjective effect from codeine when these drugs are co-administered — functionally mimicking poor metaboliser phenotypes.

Case Study: Codeine + Inhibitor Impact

A pivotal study by Armstrong & Cozza (2006) examined how CYP2D6 inhibition alters codeine metabolism. By administering quinidine or fluoxetine, they observed:

• Decreased plasma morphine levels

• Reduced pain relief

• Decreased subjective "high"

These findings reinforce the clinical importance of CYP2D6-mediated morphine production. The authors also noted an alternative hypothesis: that codeine’s primary active metabolite might be codeine-6-glucuronide (C6G) — produced via UGT2B7 — a possibility that still requires clinical confirmation.

Clinical Implications: PGx or Policy?

In the UK, the BNF discourages codeine in patients under 18, particularly post-ENT surgery. The FDA and EMA have issued similar warnings for breastfeeding mothers, following multiple cases of infant death linked to ultrarapid metabolism.

Globally, regulatory trends are shifting. Many countries — including France, Australia, and parts of the EU — now restrict codeine to prescription-only use.

Amid these shifts, the case for routine pharmacogenomic (PGx) testing grows stronger — especially in patients who:

• Are children or adolescents

• Are undergoing repeat or chronic codeine therapy

• Report poor response to standard codeine doses

• Are on concurrent CYP2D6 inhibitors

While routine PGx testing for opioids like codeine is not yet widely available on the NHS, some cancer patients may access pharmacogenomic screening—such as DPYD testing for fluoropyrimidine toxicity or TPMT testing for thiopurines—as part of standard oncology care. For pain management and mental health medications, most PGx testing remains privately accessed or research-based.

Conclusion

Codeine’s effectiveness and safety are directly tied to CYP2D6 metabolism, a pathway influenced by both genetics and drug interactions. With the ability to identify poor and ultrarapid metabolisers through pharmacogenetic testing, clinicians can make safer prescribing decisions. As UK policies evolve, integrating CYP2D6 PGx testing into opioid workflows isn’t just ideal — it’s essential.

Request a PGx Demo